Allakos (ALLK) Revenue & Revenue Breakdown
Allakos Revenue Highlights
Allakos Revenue by Period
Allakos Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | - |
Allakos generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Allakos Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $10.76M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | - |
Allakos generated - in revenue during Q1 2024, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Allakos Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RARE | Ultragenyx Pharmaceutical | $434.25M | $147.03M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| SGMO | Sangamo Therapeutics | $176.23M | $356.00K |
| HRTX | Heron Therapeutics | $127.04M | $46.54M |
| RCUS | Arcus Biosciences | $117.00M | $39.00M |
| CTMX | CytomX Therapeutics | $101.21M | $25.11M |
| SPRO | Spero Therapeutics | $96.73M | $10.20M |
| GTHX | G1 Therapeutics | $82.51M | $16.55M |
| ARVN | Arvinas | $78.50M | $76.50M |
| FATE | Fate Therapeutics | $63.53M | $6.77M |
| CRBU | Caribou Biosciences | $34.48M | $3.46M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| ATRA | Atara Biotherapeutics | $8.57M | $28.64M |
| ASMB | Assembly Biosciences | $7.16M | $5.79M |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| KRTX | Karuna Therapeutics | $654.00K | - |
| ALLO | Allogene Therapeutics | $95.00K | $22.00K |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| NXTC | NextCure | - | - |
| KURA | Kura Oncology | - | - |
| ANNX | Annexon | - | - |
| NLTX | Neurogene | - | - |
| SANA | Sana Bio | - | - |
| ALLK | Allakos | - | - |
ALLK Revenue FAQ
What is Allakos’s yearly revenue?
Allakos's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. ALLK's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Allakos’s quarterly revenue?
Allakos's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $10.76M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022). ALLK's quarterly revenue for Q3 2023 was $0, a 100.00% increase from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022).
What is Allakos’s revenue growth rate?
Allakos's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.